Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.
Year: 2018
Type: article
Abstract: OBJECTIVES: To estimate the costs of providing extended-release injectable naltrexone (XR-NTX) and buprenorphine-naloxone (BUP-NX) following inpatient detoxification using data derived from a multisite randomized controlled trial at 8 US community-based treatment programs. STUDY DESIGN: Cost data were collected for 3 intervention phases: program start-up, inpatient detoxification, and up to 24 weeks of medication induction and management visits (post detoxification). Cost analyses were from the healthcare sector perspective (2015 US$); patient costs are also reported. METHODS: We conducted site visits, administered a cost survey to treatment programs, and analyzed study data on medication and services utilization. Nationally representative sources were used to estimate unit costs. Uncertainty was evaluated in sensitivity analyses. RESULTS: Mean start-up costs were $1071 per program for XR-NTX and $828 per program for BUP-NX. Mean costs per participant were $5416 for XR-NTX (57% detoxification, 37% medication, 3% provider, 3% patient) and $4148 for BUP-NX (64% detoxification, 12% medication, 10% provider, 14% patient). Total cost per participant ranged by site from $2979 to $8963 for XR-NTX and from $2521 to $6486 for BUP-NX. CONCLUSIONS: For treatment providers, offering XR-NTX and/or BUP-NX as part of existing detoxification treatment modalities generates modest costs in addition to the costs of detoxification, which vary substantially among the 8 sites. From the patient's perspective, the costs associated with medication management visits may be a barrier for some individuals considering these treatments.
Source: PubMed
Authors: Kathryn E McCollister, Jared A Leff, Xuan Yang, Joshua D Lee, Edward V Nunes, Patricia Novo, John Rotrosen, Bruce R Schackman, Sean M Murphy
Institutions: University of Miami, University of Miami Health System
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Florida Node Alliance of the Drug Abuse Clinic Trials Network, Clinical Trials Network: Greater New York Node, Drug Abuse Treatment Development and Research Mentoring, NIDA Clinical Trials Network - New York Node, Clinical Trials Network, Ohio Valley Node U10DA013732, Economic Evaluation of Medication-Assisted Substance Abuse Treatment, The National Drug Abuse Treatment Clinical Trials Network, The National Drug Abuse Treatment Clinical Trials Network (U10), Clinical Trials Network: Southwest Node, Clinical Trials Network Mid-Atlantic Collaborative Group, CTN New England Consortium Node, NIDA Clinical Trials Network: New York Node - Renewal-GY24, Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation, The Florida Node Alliance of the National Drug Abuse Clinical Trials Network, Clinical Trials Network: Pacific Northwest Node
OpenAlex ID: W2916442394